Tri Locum Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Tri Locum Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$53.4M	Buy	221,720 +63,057	+40%	+$13.8M	6.57%	7
2026 Q1	$30M	Buy	+158,663	New	+$27.7M	4.21%	12
2025 Q1	–	Sell	-161,812	Closed	-$19.9M	–	29
2024 Q4	$19.9M	Buy	+161,812	New	+$19.1M	4.13%	11
2022 Q4	–	Sell	-106,528	Closed	-$14.2M	–	84
2022 Q3	$14.2M	Buy	106,528 +49,165	+86%	+$7.48M	3.9%	8
2022 Q2	$8.95M	Sell	57,363 -73,315	-56%	-$11.3M	3.66%	11
2022 Q1	$20.3M	Buy	+130,678	New	+$19M	7.95%	1
2021 Q3	–	Sell	-89,370	Closed	-$15.9M	–	36
2021 Q2	$15.9M	Sell	89,370 -21,012	-19%	-$3.64M	5.2%	6
2021 Q1	$18.1M	Buy	+110,382	New	+$18.2M	4.5%	10

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Tri Locum Partners's JAZZ Position: Q2 2026 in Review

Tri Locum Partners increased its Jazz Pharmaceuticals (JAZZ) stake by 40% in Q2 2026, buying an estimated $13.8M and bringing the position to 221,720 shares worth $53.4M. The position accounts for 6.57% of the portfolio, ranked #7.

Tri Locum Partners first reported a position in JAZZ in Q1 2021 and has held it in 8 quarters since. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Tri Locum Partners held 221,720 shares of Jazz Pharmaceuticals worth $53.4M as of Q2 2026.
Tri Locum Partners bought 63,057 Jazz Pharmaceuticals shares in Q2 2026, an estimated $13.8M.
Jazz Pharmaceuticals made up 6.57% of Tri Locum Partners's portfolio in Q2 2026, its #7 holding.
Tri Locum Partners first reported a position in Jazz Pharmaceuticals in Q1 2021 and has held it in 8 quarters since.
646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Tri Locum Partners's 13F filing for Q2 2026, filed 14 Aug 2026.